Literature DB >> 17914664

Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats.

Ashraf Yassen1, Erik Olofsen, Jingmin Kan, Albert Dahan, Meindert Danhof.   

Abstract

OBJECTIVE: Respiratory depression is a serious and potentially life-threatening side-effect of opioid therapy. The objective of this investigation was to characterize the relationship between buprenorphine or fentanyl exposure and the effectiveness and safety outcome in rats.
METHODS: Data on the time course of the antinociceptive and respiratory depressant effect were analyzed on the basis of population logistic regression PK-PD models using non-linear mixed effects modeling software (NONMEM). The pharmacokinetics of buprenorphine and fentanyl were described by a three- and two-compartment model, respectively. A logistic regression model (linear logit model) was used to characterize the relationship between drug exposure and the binary effectiveness and safety outcome.
RESULTS: For buprenorphine, the odds ratios (OR) were 28.5 (95% CI, 6.9-50.1) and 2.10 (95% CI, 0.71-3.49) for the antinociceptive and respiratory depressant effect, respectively. For fentanyl these odds ratios were 3.03 (95% CI, 1.87-4.21) and 2.54 (95% CI, 1.26-3.82), respectively.
CONCLUSION: The calculated safety index (OR(antinociception)/OR(respiratory depression)) for fentanyl of 1.20 suggests that fentanyl has a low safety margin, implicating that fentanyl needs to be titrated with caution. For buprenorphine the safety index is 13.54 suggesting that buprenorphine is a relatively safe opioid.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914664      PMCID: PMC2190336          DOI: 10.1007/s11095-007-9440-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

2.  The minimum effective concentration of opioids: a revisitation with patient controlled analgesia fentanyl.

Authors:  A Woodhouse; L E Mather
Journal:  Reg Anesth Pain Med       Date:  2000 May-Jun       Impact factor: 6.288

3.  Severe respiratory depression and sedation with transdermal fentanyl: four case studies.

Authors:  Claud Regnard; Anne Pelham
Journal:  Palliat Med       Date:  2003-12       Impact factor: 4.762

4.  Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data.

Authors:  Gordon Graham; Suneel Gupta; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

5.  Old dog--new (ma)trix.

Authors:  K Budd; B J Collett
Journal:  Br J Anaesth       Date:  2003-06       Impact factor: 9.166

Review 6.  The utility function of antihypertensive therapy.

Authors:  L B Sheiner; K L Melmon
Journal:  Ann N Y Acad Sci       Date:  1978-03-30       Impact factor: 5.691

Review 7.  Buprenorphine: a primer for emergency physicians.

Authors:  Karl A Sporer
Journal:  Ann Emerg Med       Date:  2004-05       Impact factor: 5.721

8.  Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers.

Authors:  Raymonda Romberg; Erik Olofsen; Elise Sarton; Luc Teppema; Albert Dahan
Journal:  Anesthesiology       Date:  2003-10       Impact factor: 7.892

Review 9.  Definitions of "respiratory depression" with intrathecal morphine postoperative analgesia: a review of the literature.

Authors:  Samuel Ko; David H Goldstein; Elizabeth G VanDenKerkhof
Journal:  Can J Anaesth       Date:  2003 Aug-Sep       Impact factor: 5.063

10.  Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine.

Authors:  Ashraf Yassen; Erik Olofsen; Jingmin Kan; Albert Dahan; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more
  18 in total

1.  Pharmacokinetics of sustained-release analgesics in mice.

Authors:  Lon V Kendall; Ryan J Hansen; Kathryn Dorsey; Sooah Kang; Paul J Lunghofer; Daniel L Gustafson
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

2.  Antinociceptive effects of sustained-release buprenorphine in a model of incisional pain in rats (Rattus norvegicus).

Authors:  Helen H Chum; Katechan Jampachairsri; Gabriel P McKeon; David C Yeomans; Cholawat Pacharinsak; Stephen A Felt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-03       Impact factor: 1.232

Review 3.  Differences between opioids: pharmacological, experimental, clinical and economical perspectives.

Authors:  Asbjørn M Drewes; Rasmus D Jensen; Lecia M Nielsen; Joanne Droney; Lona L Christrup; Lars Arendt-Nielsen; Julia Riley; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

4.  Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats.

Authors:  Patricia L Foley; Haixiang Liang; Andrew R Crichlow
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-03       Impact factor: 1.232

5.  μ-Opioid Receptor Agonists: Do They Have Utility in the Treatment of Acute Pain?

Authors:  Thomas K Henthorn; Susan K Mikulich-Gilbertson
Journal:  Anesthesiology       Date:  2018-05       Impact factor: 7.892

6.  Effects of Standard and Sustained-release Buprenorphine on the Minimum Alveolar Concentration of Isoflurane in C57BL/6 Mice.

Authors:  Philip C LaTourette; Emily M David; Cholawat Pacharinsak; Katechan Jampachaisri; Jennifer C Smith; James O Marx
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-04-08       Impact factor: 1.232

7.  Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice.

Authors:  Tannia S Clark; David D Clark; Robert F Hoyt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-07       Impact factor: 1.232

8.  Buprenorphine for Chronic Pain: a Systemic Review.

Authors:  Michael A Fishman; Phillip S Kim
Journal:  Curr Pain Headache Rep       Date:  2018-10-05

Review 9.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

10.  Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups.

Authors:  Christian Martini; Ashraf Yassen; Erik Olofsen; Paul Passier; Malcom Stoker; Albert Dahan
Journal:  J Pain Res       Date:  2012-03-15       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.